The University of Texas MD Anderson Cancer Center and Myriad Genetics (MYGN) have entered into a five-year strategic alliance. This partnership is designed to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.
Under the terms of the agreement, MD Anderson and Myriad Genetics will collaborate to design both retrospective and prospective studies. These studies will investigate the test’s utility in breast, gastrointestinal, genitourinary, and gynecological cancers. The primary objective of these studies is to generate evidence that supports the inclusion of the MRD assay in national guidelines and its adoption by healthcare providers.
MD Anderson investigators will take the lead in patient enrollment, sample collection, clinical data analysis, and manuscript writing. On its part, Myriad will provide funding, MRD testing, and scientific research support. Additionally, the collaboration may include potential milestone and royalty payments.
